Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Recruiting
Observational Study
Multiple Sclerosis
NMO Spectrum Disorder
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Radiologically Isolated Syndrome
Clinically Isolated Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 7,000 (estimated)
- Sponsor
- icometrix · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to deve…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* Patients must have a confirmed diagnosis of MS, NMOSD, MOGAD, CIS or RIS.
* Patient (or patient's legal representative) has previously signed and dated an informed consent form (ICF) for the secondary use of their data, or assent form. Alternatively, the secondary use of the p…
Contacts